The Cancer Biopsy Market was dominated by North America in 2023, mainly due to the strong healthcare infrastructure, massive investment in R&D, and strong presence of market leader companies. The United States remains technologically advanced in cancer diagnostics. Companies such as Roche and Thermo Fisher Scientific have been consistently introducing novel biopsy technologies to improve the care quality of patients in the region, which gives North America a strong grip on the Cancer Biopsy Market.